ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

This study is a randomized, multicenter, Phase Ib/II clinical trial, aimed at evaluating the efficacy and safety of the combination of ZG006 and ZG005 in patients with advanced small cell lung cancer and neuroendocrine carcinoma.

Trial Details

NCT ID
NCT07038096
Phase
PHASE1 / PHASE2
Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • ZG006
  • ZG005
Locations (sample)
  • Guanzhou, Guangdong, China|23.06828,113.37117

Key Eligibility Criteria

  • Fully understand the study and voluntarily sign the informed consent form.
  • Male or female 18-70 years of age.
  • Participants with advanced small cell lung cancer or neuroendocrine carcinoma confirmed by histopathology or cytology.
  • Eastern Cooperative Oncology Group (ECOG) 0 to 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →